Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2006-10-17
2006-10-17
Witz, Jean C. (Department: 1651)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
Reexamination Certificate
active
07122579
ABSTRACT:
The present invention involves the discovery that synthetic thyroid hormones can be used as compositions to reduce intraocular pressure in vivo. Methods of screening synthetic thyroid hormones for effect on intraocular pressure, aqueous pressure, hydraulic conductivity, hyaluronic acid secretion, and extracellular matrix assembly are provided. Methods of treating glaucoma and treating excess intraocular pressure with synthetic thyroid hormones and compositions therefore are also provided.
REFERENCES:
patent: 2798053 (1957-07-01), Brown
patent: 4038264 (1977-07-01), Rostoker et al.
patent: 4136250 (1979-01-01), Mueller et al.
patent: 4192827 (1980-03-01), Mueller et al.
patent: 4548990 (1985-10-01), Mueller et al.
patent: 4870106 (1989-09-01), Shihao
patent: 5474985 (1995-12-01), Polansky et al.
patent: 5486165 (1996-01-01), Stegmann
patent: 6221911 (2001-04-01), Lavin et al.
patent: 6380255 (2002-04-01), Lavin
patent: 253717 (1988-01-01), None
patent: WO 95/17178 (1995-06-01), None
patent: WO 96/40048 (1996-12-01), None
patent: WO 97/21993 (1997-06-01), None
Alekseeva, Izv, Sibirsk. Otd. Akad. Nauk SSR, Ser. biol-Med, Nauk(2): 108-112 (1963).
Capechi, M. R. (1994) “Targeted Gene Replacement”Scientific American, 270(3):34-41.
Lund et al, Acta Endrocrinol. 113(1):56-58 (1986).
McDaniel et al., Journal of American Optometric Associate 67(2):109-114 (Feb. 1998).
Schiller et al., Biochim. Biophys. Acta 58-27-33 (1962).
Wall, R.J. (1996) “Transgenic Livestock: Progress and Prospects for the Future”Theriogenology, 45:57-68.
Wildmeister et al., Med. Welt 28(41): 1652-1655 (1977).
Yoneyama, J. (1994) “Effects of Antiglaucoma Agents on Glycosaminoglycans in Organ-Cultured Rabbit Trabecular Meshwork”Ophthalmologica, 208(5):278-283.
Alvarado et al., “Human trabecular cells II, Growth Pattern and Ultrastructural Characteristics”, Invest, Ophthalmol. Vis. Sci., vol. 23;464-478 (1982).
Apriletti J. et al., “Large Scale Purification of the Nuclear Thyroid Hormone Receptor from Rat Liver and Sequence-specific Binding of the Receptor to DNA”, J. Biol. Chem. vol. 263:9409-9417 (1988).
Apriletti J. et al., Expression of the Rat 1 Thyroid Hormone Receptor Ligand Binding Domain in Escherichia Coli and the Use of a Ligant-Induced Conformation Change as a Method for Its Purification to Homogensity, Protein Expression and Purification, vol. 6:362-370 (1995).
Ashton, P. et al., “Review, Implants”, J. of Oco. Pharm., vol. 10:691-701 (1994).
Hallman V.L., “Effect of Thyroid Hormones on Intraocular Pressure,” Exptl. Eye Res., vol. 6:219-226 (1967).
Jorgensen, “Thyroid Hormones and Analoge”, in Hormonal Proteins and Peptides, vol. 6, Thyroid Hormones (Choh Hao Li, ed.) pp. 107-204 (1978).
Lam et al., “Hydraulie Flow Conductivity of Hyaluronic Acid Solutions: Effects on Concentration and Molecular Weight,” Biorheology, vol. 27:789-795 (1990).
Lavin T.N. “Mechanisms of Thyroid Hormone Action”, in Endocrinology (Degroot, Ed.), 2nd Edition, W.B. Saunders, pub. (1999).
Lewis et al., “Formation of Quinol Ethers using (Diacetoxyiodo) benzene”, Synthesis, vol. 1103 (1987).
Murphy, B.P. et al., “The Determination of Thyroxine by Conpetitive Protein-binding Analysis Employing an Anion-exchange Resin and Radiothyroxine”, J. Lab and Clin. Med., vol. 66:161-167 (1965).
Oppenheimer, J.H. et al., “Stereospacific Transport of Triiodothyronine from Plasma to Cytosol and from Cytosol to Nucleus in Rat Liver, Brain, and Heart”, J. Clin. Invest., vol. 75:147-154 (1985).
Polansky et al., “Trabecular Meshwork Cell Culture in Glaucoma Research, Evaluation of Biological Activity and Structural Properties of Human Trabecular Cell In Vitro”, Opthalmology, vol. 91:580-595 (1984).
Polansky et al., Studies on human trabecular cells propagated in vitro, Vision Res., vol. 21:155 (1981).
Polansky et al., Human trabecular cells I: Establishment in tissue culture and growth characteristics, Invest. Opthalmol. Vis. Sci. vol. 18:1043-1049 (1979).
Ribeiro et al., “Thyroid Hormone Export Regulates Cellular Hormone Content and Response,” The Journal of Biological Chemistry, vol. 271(29):17147-17151 (1996).
Samuels et al., “Depletion of L-2, 5.3′-Triiodothyronine and L-Thyroxins in Euthyroid Calf Serum for Use in Cell Culture Studies of the Action of Thyroid Hormons”, J. Endocrinology, vol. 105(1):80-85 (1979).
Schwarts, H.L., et al., “Distribution and Metabolism of L-and D-Triiodothyronine (T3) in the Rat: Preferential Accumulation of L-T3 by Hepatic and Cardiac Nuclei as a Probable Explanation of the Differential Biological Potency of T3 Enantiomers”, Endrocronology vol. 113:1236 (1983).
Schwarts, H.L. et al., “Quantitation of Rat Tissue Hormone Binding Receptor Isoforms by Immunoprecipitation of Nuclear Triiodothyronine Binding Capacity”, J. Biol. Chem., vol. 267(17):11794-11799 (1992).
Shishiba et al., Effect of Thyroid Hormone Deficiency on Proteoglycan Synthesis by Human Skin Fibroblast Cultures, Connective Tissue Research, vol. 17:119-135 (1988).
Smith et al., “An ocular dynamic study supporting the hypothesis that hypothyroidism is a treatable cause of secondary open-angle glaucoma,” Can, J. Opthtahmology, vol. 27(7):341-344 (1992).
Smith et al., “An Association between Hypothyroidism and Primary Open-Angle Glaucoma,” Opthalmology, vol. 100(10):1580-1584 (1992).
Smith T.J. et al., “Regulation fo Glycosaminoglycan Synthesis by Thyroid Hormone in Vitro,” J. Clin. Invest., vol. 70:1066-1073 (1982).
Smith T.J., The Effect of Thyroid Hormone on Glycosaminoglycan Accumulation in Human Skin Fibroblasts, Endocrinology, vol. 109(6):2397-2399 (1981).
Stern & Stern, “An ELIGA-Like Assay for Hyaluronidase and Hyaluronidase Inhibitors”,Matrix, vol. 12(5):397-403 (1992).
Baxter John D.
Jumper Michele D.
Scanlan Thomas S.
Schwartz Daniel M.
Baker Gary
Quine Intellectual Property Law Group P.C.
The Regents of the University of California
Witz Jean C.
LandOfFree
Eye treatments using synthetic thyroid hormone compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Eye treatments using synthetic thyroid hormone compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Eye treatments using synthetic thyroid hormone compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3651085